2023 Highlights

Montefiore Einstein Cardiology

In 2023, Montefiore Einstein Cardiology advanced its leadership in cardiac care and research, making groundbreaking strides in heart transplantation, structural valve interventions and arrhythmia management, while also expanding its state-of-the-art imaging program. This commitment to innovation, alongside significant contributions to scientific research and global education, underscores Montefiore Einstein's dedication to providing the highest quality of care.


2023 by the numbers


one year adult heart transplant survival


cardiac arrhythmia management cases


diagnostic, interventional and structural heart procedures


diagnostic cardiac imaging studies

Research Review

Improving care and outcomes through research

In 2023, we published over 180 publications including 60 scientific articles in imaging featured in Nature communications, JACC, Eur Heart J, JAMA Cardiology, Circulation, Circ CVI and more.

Clinical Trials

Advancing care through clinical trials

We participated in over 30 clinical trials in 2023, spanning from novel drugs through advanced devices for the treatment of heart failure, valvular heart disease and arrhythmias. Our investigators performed several first-in-human procedures that sought to offer better treatment options for patients with heart disease.

Pragmatic Evaluation of Events And Benefits of Lipid-lowering in Older Adults (PREVENTABLE trial)

Carlos Rodriguez, MD

The SPYRAL AFFIRM Global Clinical Study of Renal Denervation with the Symplicity Spyral Renal Denervation System in Subjects with Uncontrolled Hypertension (SPYRAL AFFIRM)

Azeem Latib, MD
Maday Gonzalez, MD

TRISCEND II Pivotal Trial - Edwards Lifesciences EVOQUE Valve for Severe TR

Azeem Latib, MD

PROGRESS: Management of Moderate Aortic Stenosis by Clinical Surveillance or TAVR (PROGRESS)

Edwin Ho, MD

Transcatheter Mitral Valve Replacement With the Medtronic Intrepid™ TMVR System in Patients With Severe Symptomatic Mitral Regurgitation. (APOLLO)

Azeem Latib, MD

A Multicenter, Randomized, Double-Blind, Parallel Group, Placebo-Controlled Trial to Evaluate the Effect of In-Hospital Initiation of Dapagliflozin on Clinical Outcomes in Patients Who Have Been Stabilized During Hospitalization for Acute Heart Failure

Snehal Patel, MD

A Randomized, Sham-controlled, Blinded (Patient and Evaluators) Feasibility Trial of the Edwards APTURE Transcatheter Shunt System (ALT-FLOW II)

Sandhya Murthy, MD

Clinical Evaluation of the AccuCinch® Ventricular Restoration System in Patients who Present with Symptomatic Heart Failure with Reduced Ejection Fraction (HFrEF): The CORCINCH-HF Study

Yogita Rochlani, MD

A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing the Impact of Olpasiran on Major Cardiovascular Events in Patients with Atherosclerotic Cardiovascular Disease and Elevated Lipoprotein (a)

Leandro N. Slipczuk Bustamante, MD

Post-Market Real World Outcomes in WATCHMAN FLX™ Pro Left Atrial Appendage Closure (LAAC) Device

Luigi Di Biase, MD

Assessment of Safety and Effectiveness in Treatment Management of Atrial Fibrillation With the BWI IRE Ablation System (AdmIRE)

Luigi Di Biase

Growing our footprint with new state-of-the-art facilities

We expanded our footprint, opening Montefiore Einstein Advanced Care—Westchester and new outpatient clinics at White Plains Hospital, Wakefield Campus and Montefiore Heart Failure Center at Nyack Hospital. We are also finalizing plans for a comprehensive heart failure initiative, which will include specialty clinics for amyloid, sarcoid, hypertrophic cardiomyopathy and pulmonary hypertension, cardiac intensive care consultations at Nyack Hospital and a new catheterization laboratory. This initiative marks a major step toward advancing Montefiore’ Einsteins footprint and heart failure expertise in New York’s Hudson Valley region.

Patient referrals

At Montefiore Einstein Cardiology, we know that providing patients with the best possible care includes teamwork and trust. We work closely with our valued referring physicians to ensure open communication and reliable expertise.